IL-6 production following vaccination in pigs-An additional immune response parameter for assessing FMD vaccine efficacy?

Vaccine

Volumn 29, Issue 29-30, 2011, Pages 4704-4708

  Cox, Sarah J ^a   Gubbins, Simon ^a   Barnett, Paul V ^a  

^a INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

Author keywords

Foot and mouth disease vaccine; Interleukin 6; Potency test; Swine

Indexed keywords

ANTIBODY; FOOT AND MOUTH DISEASE VACCINE; INTERLEUKIN 6;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BLOOD; BLOOD SAMPLING; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOT AND MOUTH DISEASE; FOOT AND MOUTH DISEASE VIRUS; IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SWINE; VACCINATION;

EID: 79960630578     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.100     Document Type: Article

References (15)

1. Anon. Foot-and-mouth disease (ruminants) vaccine (inactivated). In: European Pharmacopoeia; 2008. p. 60.
2. Anon. Requisitos para acresitacion de sistemas nacionales para el control de calidad de vacuna antiaftosa. In: Centro Panamericano de Fiebre Aftosa, version 1.0; 2002.
3. Barnett PV, Statham RJ, Vosloo W, Haydon DT. Foot-and-mouth disease vaccine potency testing: determination and statistical validation of a model using a serological approach. Vaccine 2003;21:3240-8.
4. Goris N, Willems T, Diev ID, Merkelbach-Peters P, Vanbinst T, et al. Indirect footand-mouth disease vaccine potency testing based on a serological alternative. Vaccine 2008;26:3870-9.
5. Maradei E, La Torre J, Robiolo B, Esteves J, Seki C, et al. Updating of the correlation between lpELISA titers and protection from virus challenge for the assessment of the potency of polyvalent aphtovirus vaccines in Argentina. Vaccine 2008;26:6577-86.
6. Jamal SM, Bouma A, van den Broek J, Stegeman A, Chénard G, Dekker A. Footand-mouth disease vaccine potency testing: the influence of serotype, type of adjuvant, valency, ractionation method, and virus culture on the dose-response curve in cattle. Vaccine 2008;26:6317-21.
7. Cox SJ, Aggarwal N, Statham RJ, Barnett PV. Longevity of antibody and cytokine responses following vaccination with high potency emergency FMD vaccines. Vaccine 2003;21:1336-47.
8. Barnett PV, Cox SJ, Aggarwal N, Gerber H, McCullough KC. Further studies on the early protective responses of pigs following immunization with high potency foot and mouth disease vaccine. Vaccine 2002;20:3197-208.
9. OIE World Organisation for Animal Health. Foot and mouth disease. OIE Standards Commission. Manual of diagnostic tests and vaccines for terrestrial animals. 6th ed. Paris, France: Office International des Epizooties; 2008 [chapter 2.1.5].
10. van Bekkum JG. Neutraliserende antistoffen in sera van regen mond and Klauwzeer geente runderen. Thesis. University of Utrecht, Utrecht; 1959.
11. Hecke F, Uhlmann W, Lorenz R. Bericht uber die ergebnisse der grossversuchs 1957-1958 zur wirkaamkeitsprufung der Maul-und klavenseuchekoncentratvakzine nach pyl unf der originalvakzine nach waldmann und kobe IV. Beziehung zwischen serumneutralisation und immunitat. Mh Tierheildk 1960;12:1-11.
12. Mackowiak C, Lang R, Fontaine J, Camand R, Petermann MB. Relation entre titre d'anticorps neutralisants et protection des animaux après vaccination antiaphteuse. Ann Inst Pasteur 1962;103:252-61.
13. Bercan A, Muntiu N, Dohotaru U, Tomescu A. Sur la corrélation entre le test de séro-neutralization sur sourceux et immunisation anti-aphtheuse croísee chez les bovins. Bull Off Int Epizoot 1969;71:381-92.
14. Barnett PV, Keel P, Reid S, Armstrong RM, Statham RJ, Voyce C, et al. Evidence that high potency foot-and-mouth disease vaccine inhibits local virus replication and prevents the 'carrier' state in sheep. Vaccine 2004;22:1221-32.
15. Parida S, Oh Y, Reid S, Cox SJ, Statham RJ, Mahapatra M, et al. Interferon-_ production in vitro from whole blood of foot-and-mouth disease virus (FMDV) vaccinated and infected cattle after incubation with inactivated FMDV. Vaccine 2006;24:964-9.